Natalizumab (Tysabry®) is a humanised monoclonal antibodies (MAb) which blocks alpha4beta1 integrin-mediated leukocyte migration; it is one among the plethora of pharmacological treatments against multiple sclerosis (MS) [1,2]. Some reports describe a relationship between clinical syndromes and administration of Mab, in particular on thyroid gland [3,4]. Therefore, only few data have been so far reported about cardiac involvement and MAb-therapy. We report here an unusual case of acute myocardial damage likely induced by taking Natalizumab, in an young woman in treatment for a relapsing–remitting (RR) MS.
Natalizumab treatment for multiple sclerosis inducing a toxic acute myocardial damage. Is there any relationship?
Cicciu', Marco;
2016-01-01
Abstract
Natalizumab (Tysabry®) is a humanised monoclonal antibodies (MAb) which blocks alpha4beta1 integrin-mediated leukocyte migration; it is one among the plethora of pharmacological treatments against multiple sclerosis (MS) [1,2]. Some reports describe a relationship between clinical syndromes and administration of Mab, in particular on thyroid gland [3,4]. Therefore, only few data have been so far reported about cardiac involvement and MAb-therapy. We report here an unusual case of acute myocardial damage likely induced by taking Natalizumab, in an young woman in treatment for a relapsing–remitting (RR) MS.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
